
|Articles|August 28, 2012
PODCAST: Dr. Goldfischer on OAB
PODCAST Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.
Advertisement
PODCAST: Dr. Goldfischer on OAB
Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer
5











